OKs For 16 New Drugs But EMA Holds Firm On Betrixaban & Abaloparatide No
Executive Summary
The European Medicines Agency this month recommended EU marketing approval for a raft of products, including what could become Europe's first two biosimilar versions of the blockbuster drug, Neulasta.
You may also be interested in...
Tetraphase's Broad Spectrum Antibiotic Xerava Priced To Move
Company presents game plan for targeting 1,900 high-prescribing hospitals in US in a launch kicking off in the second half of October.
Stand-Off: Vertex Refuses NICE Data on CF Drug Symkevi, HTA Body Awaits Next Move
Vertex says it will not file data on its cystic fibrosis drug Symkevi (tezacaftor/ivacaftor) until the UK's NICE changes the way it assesses drugs.
Alnylam Offers Flexible Value-Based Deals For Breakthrough RNAi Drug Onpattro
The commercial team is on board and ready to market the first FDA-approved RNAi therapeutic patisiran for hereditary transthyretin-mediated amyloidosis.